Royal Bank of Canada »

Kalaris Therapeutics shares owned by Royal Bank of Canada

Quarter-by-quarter ownership of Kalaris Therapeutics (KLRS) shares owned by Royal Bank of Canada from 13F filings

Historical chart of Royal Bank of Canada investment in Kalaris Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Kalaris Therapeutics held by Royal Bank of Canada consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Kalaris Therapeutics by Royal Bank of Canada

Quarter filed Position value Share count Share price at filing
2025-09-30 $0 85 0.00
2025-06-30 $0 85 0.00

More positions owned by Royal Bank of Canada

Spdr S&p 500 Etf Tr Tr Unit (SPY)
Microsoft Corporation (MSFT)
NVIDIA Corporation (NVDA)
Apple (AAPL)
Ishares Tr Core S&p500 Etf (IVV)
Amazon (AMZN)
Toronto Dominion Bk Ont Com New (TD)
Rbc Cad (RY)
Bank Of Montreal Cadcom (BMO)
Bk Nova Cad (BNS)
Alphabet Cap Stk Cl A (GOOGL)
Invesco Qqq Tr Unit Ser 1 (QQQ)
JPMorgan Chase & Co. (JPM)
Broadcom (AVGO)
Ishares Tr Russell 2000 Etf (IWM)

View all positions for Royal Bank of Canada

Top funds holding Kalaris Therapeutics

Samsara BioCapital
Tang Capital Management
Siren
Woodline Partners
Vanguard Group
Renaissance Technologies
Redmile Group
Geode Capital Management
BlackRock
Squarepoint Ops
Fortis Capital Advisors
Belpointe Asset Management
Millennium Management
State Street Corporation
Bridgeway Capital Management

View all funds holding Kalaris Therapeutics